2 Well-liked Robinhood Shares I Would not Purchase With Free Cash

Robinhood Markets is the company behind the Robinhood investment platform. Robinhood is particularly popular with the younger generation and has received praise for its efforts to “democratize finance”. Thanks to his app, many who had never invested in stocks before are now actively doing so. When you consider that the stock market is still one of the best wealth generators for the common man, that’s not a bad thing.

That said, Robinhood investors aren’t perfect, and while the list of the company’s 100 most popular stocks on the platform has some excellent selections, others aren’t that great. Here are two popular Robinhood stocks that I wouldn’t buy with free money: Okcugen (NASDAQ: OCGN) and Inovio Pharmaceuticals (NASDAQ: INO).

1. Ocugen

Ocugen – a clinical stage biotech company that currently has no commercialized products – is playing in the coronavirus vaccine market. It’s not necessarily a losing strategy, especially for a company this size; The current market capitalization is only $ 1.45 billion. There is still some blank space in the COVID-19 vaccine market, particularly in developing countries and with the advent of newer varieties of the disease.

Image source: Getty Images.

If Ocugen receives the Emergency Use Authorization (EUA) from the US Food and Drug Administration for his candidate and even generates $ 1 billion in sales, it would be a big win for the company. However, there are a few important points to keep in mind. First, the company signed an agreement to jointly develop and commercialize its candidate Covaxin with India-based Bharat Biotech. While Ocugen will hold the commercial rights to the vaccine in the US and Canada (pending approval), it will retain only 45% of Covaxin’s profits in those countries.

Second, the prospects of an early EUA in the US for Covaxin are as good as gone. As recommended by the FDA, Ocugen is now likely to file a biologics application that will take several months longer to review than an EUA. Third, Covaxin’s ability to gain market share in this competitive environment is dubious. In a Phase 3 clinical study conducted in India with 25,798 participants, the vaccine candidate was found to be 77.8% effective against COVID-19. Its effectiveness against the rapidly spreading delta variant was 65.2%.

In the meantime they are from. developed vaccines Pfizer, Modern, and Novavax have all shown an overall effectiveness of 90% or greater. Could Covaxin’s overall effectiveness be at least partially less because the late-stage study was conducted in India, where the Delta variant originated? Maybe, but other vaccines including that of. displaced Johnson & Johnson, have also shown potency against this variant. Put all of this together and add the usual risks Biotech companies (including potential unforeseen clinical and regulatory setbacks), Ocugen seems far too risky to invest in right now.

2. Inovio Pharmaceuticals

Inovio Pharmaceuticals also hopes to enter the COVID-19 market with its candidate INO-4800. However, the biotech’s prospects are even worse than Ocugen’s. Inovio faces at least two major challenges. First, the company is unable to conduct a Phase 3 clinical trial in the US because regulators have raised concerns about the proprietary device it uses to deliver its Cellectra 2000 vaccine.

Second, the US government withdrew funding for the Phase 3 portion of its Phase 2/3 study for INO-4800. As a clinical-stage biotech, Inovio is not generating product sales, and while it received grants last year to support its coronavirus-related efforts, the company will have a hard time getting additional ones with several vaccines that are now widely available Gaining third-party funding. Party grants.

So is the INO-4800 destined to stay in Inovio’s late-stage pipeline forever? Not necessarily. The company plans to conduct a phase 3 clinical trial in Asia and South America in collaboration with Advaccine Biopharmaceuticals Suzhou. The trial, due to start before the end of summer, will test the safety and effectiveness of two doses of the vaccine candidate given one month apart. In theory, Inovio could also make decent sales on INO-4800 given the advent of newer variants of the virus. However, until the phase 3 study is completed, it is impossible to predict how much the coronavirus vaccine market will still be able to gain.

Time isn’t on Inovio’s side, and betting that the company’s master plan comes true seems speculative. In short, it would be best to stay away from this company – at least for now.

This article represents the opinion of the author who may disagree with the “official” referral position of a premium advisory service from the Motley Fool. We are colorful! Questioning an investment thesis – even one of our own – helps us all think critically about investing and make decisions that will help us get smarter, happier, and richer.

2 Extremely-Dangerous Shares I Would not Purchase With Free Cash

When you receive a ton of money, or get caught in some money unexpectedly, it might be tempting to spend that money on something you normally wouldn’t – like a high risk investment. After all, if you lose the money, you will be no worse off than before, and if you guess right, the payout could be substantial. But every decision comes with an opportunity cost. Even if you can afford to lose the money, you might be missing out on better opportunities.

And so, even if someone gave me free money to invest, I still wouldn’t like it for risky stocks. waste Okcugen (NASDAQ: OCGN) or TAL training (NYSE: VALLEY). These stocks have already resulted in significant losses for investors this year and are currently simply bad buys.

Image source: Getty Images.

1. Ocugen

Ocugen’s share price rose more than 260% in 2021 as the S&P 500 has only increased by 17%. The surge was fueled by hope that Covaxin, the COVID-19 vaccine candidate that Ocugen is jointly developing with India’s Bharat Biotech, will generate significant revenue for the Health company. The good news is that the results look promising – Ocugen reported in July that Phase 3 results showed Covaxin was over 93% effective in preventing severely symptomatic cases of COVID-19.

But even if Delta variant cases increase, meaning that another vaccine might still be needed in the US, it still may not mean much market share for Ocugen. Under the agreement with Bharat, Ocugen will receive 45% of the profits generated in the US and Canadian markets. In these countries, vaccination rates are among the highest in the world – more than 50% of people have already received at least one dose of a vaccine. And in the US, the company is no longer seeking emergency approval from the Food and Drug Administration (FDA), as the agency has proposed filing a license application for biologics instead. This is a lengthy process that could mean Covaxin will not be available for several months.

Buying a stock based on a trend like COVID-19 can be risky as things change quickly. Although the US economy has reopened in many places, there is a risk of further restrictions as the number of cases increases. It’s hard to predict how long this pandemic will last. And in the midst of this uncertainty, Ocugen investors quickly sold the stock. Its stocks are down more than 40% in the past three months, while the S&P 500 is up more than 4% during that time.

The company had no revenue for the first three months of 2021, and investors who still hold the stock are likely to bet on the success of its vaccine candidate. Ocugen doesn’t have much in the pipeline, and while Covaxin may make some revenue for the company if it gets OK from health officials in Canada or the US (which is by no means a guarantee), it’s just not a great place to invest your money right away. There are better and safer ways so that you last for the long term.

2. TAL training

China-based tutoring company TAL Education seemed like a promising investment at some point, with sales of $ 4.5 billion in 2021, up 37% from last year.

But despite this impressive growth, investing in this business is even riskier than buying Ocugen stock. And that’s because the Chinese government is cracking down on tutoring companies to cut costs for parents. In July, Reuters reported that the country would ban for-profit tuition in “core school subjects”.

While many investors prepared for some restrictions, such sluggish ones came as a shock. TAL Education stocks are now down a staggering 90% in just three months. Brokers have slashed their price targets on the stock to below $ 9 (previously, some expected them to go as high as $ 85).

Presumably, TAL Education will still be able to make a profit in non-core subjects, but even in the best case scenario, the sum will only be a fraction of what it generated before. Analysts out City group say the restrictions for industry leaders could mean a 70% drop in sales for kindergarten through 12th grade (the main focus of TAL Education).

TAL Education appears to have been taken by surprise by these recent developments, so it has canceled the scheduled release of its earnings report for the first quarter, previously slated for August 5th. The stock is an incredibly risky investment right now. and it’s just not worth taking a chance – even with free money.

This article represents the opinion of the author who may disagree with the “official” referral position of a premium advisory service from the Motley Fool. We are colorful! Questioning an investment thesis – even one of our own – helps us all think critically about investing and make decisions that will help us get smarter, happier, and richer.

Mattress Bathtub and Past will get uncommon purchase ranking, however 2 merchants would not chunk

Bed bath and beyond can be out of reach.

Although the retailer received a rare buy rating this week from B. Riley, who initiated the name with a price target of $ 44 and an upbeat argument for its new management and cost-cutting strategies, the stock doesn’t look particularly attractive at its current levels, two said Dealer to CNBC “Trading nation” on Thursday.

The $ 3.5 billion company Profit and sales growth forecasts looks maybe better than those of its industry peers, but still lags behind the broader market, said Gina Sanchez, founder and CEO of Chantico Global, in an interview on Thursday.

“It’s really hard to get upset,” she said. “We think they’re the right price and that’s not necessarily a screaming buy.”

Bed Bath and Beyond has already risen 78% since the beginning of the year and is trading at a multiple of almost 20.5 times the forward price / earnings ratio.

The history of the stock as a Reddit favorite is also doing investors a disservice, Sanchez said.

“Once that momentum takes hold in the market, you’re pretty late because these momentum trades on some of these meme stocks have nothing to do with fundamentals,” she said. “If you buy it just for the momentum, that’s the worst reason to buy because you will inevitably be the bigger fool in this story.”

One possibility that could develop has to do with Bed Bath and Beyond’s brief interest, said Matt Maley, chief marketing strategist at Miller Tabak, in the same “Trading Nation” interview.

Both times this year the stock got swept up in Reddit trading – first when GameStop rallied in January and again when AMC skyrocketed in June – it had remarkably high short interest, Maley said.

Zoom In Icon Arrows pointing outwards

“Now it’s down again. If anything, it’s got incredibly low short interest, not a high one. So people have to be very, very careful,” warned Maley. “If we … get another short squeeze, Bed Bath and Beyond won’t be one of the stocks being squeezed like that.”

While the company’s recovery history may sound promising, it will likely take time for the stock to reflect, the strategist said.

“They’ve made some good changes and their revenue has been pretty good, but I just don’t think people should be looking for another rocket ship like we’ve seen twice this year,” he said hey.

Disclaimer of Liability

Ulrika Jonsson would not ‘rule out’ getting married once more | Leisure

Ulrika Jonsson would not “rule out” getting married again.

The 53-year-old star has been married three times, but she insists that the fourth time she walked down the aisle she wouldn’t say no as she admits “giving a lot of love”.

She said, “I am a hedonist and a spontaneous person who believes in love. Although it would be strange to remarry, I can never rule it out in the future. I remember saying to a friend after my second divorce “You have my permission to shoot me if I ever get married again”.

“She obviously didn’t have a gun when I went and did it anyway! My last marriage was 12 years and the first was seven, so they took a decent amount of time. I have a lot of love to give. But the words” marriage “and” Ulrika Jonsson “have an image problem. You need really good PR.”

And Ulrika announced that she regularly speaks to her children about her “sexual awakening”.

She wrote for The Sun newspaper, adding, “I am having a sexual awakening. I have felt very much a sexual being for many years. I tell my children this regularly – much to their horror – but I repeat it. They have their fingers in their ears and they pretend to be sick.

“But it’s important that women my age are not put in a box and silenced. Everything I’ve been through has made me stronger and believed in me more than ever.”

Jodie Turner-Smith would not make one other motion film whereas pregnant | Leisure

Jodie Turner-Smith wouldn’t make another action film while pregnant.

The 34-year-old actress, who has an 11-month-old daughter Janie with husband Joshua Jackson, plays Navy Seal Karen Greer on “Without Remorse,” and although she did her best to take care of herself during the film, she doesn’t do that. “I don’t think she would do anything as strenuous again if she had another baby.

She said, “I had to take care of myself. Afterwards, would I do an action movie while I was pregnant again? No way.”

“It is so often taken for granted when women have children that you just have to assert yourself and carry on and cannot slow down when in reality you have to give yourself as much time and space as possible.

“I’m glad I did, it was an experience, but my body needed a lot more rest and relaxation than I gave it.”

And Jodie wasn’t able to “suspend” many of the action scenes

She told Total Film, “I haven’t had the opportunity to miss a lot of action scenes!

“Stefano (Sollima, director) captures as much as possible with the actors. So when it came to explosions and the like, we were really there.

“There’s an intense scene with the plane. When we were filming this, there were certain things with hydraulics and tremors that I wouldn’t do because of my baby, but when it came to getting blown up and being in an exchange of fire I did it. I also had a knife fight. “

And Jodie found it particularly “tough” because there were so few women on set.

She said, “There was another woman in the cast. And I did it when I was pregnant! It was tough. Everyone obviously supported us, but men don’t have the same priorities as women and don’t understand what the body is a woman goes through.

“So you try to fill the gap with as much communication as possible.”